Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 1/20 | 0.57 |
| ▸ | FDPS | P14324 | 1/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909196 | 0.85 | GGPS1 (0.55) | GGPS1FDPSGPR84NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8661446 | 0.84 | GGPS1 (0.54) | GGPS1FDPSGPR84NPC1RAB9A | |
| SCHEMBL21936885 | 0.84 | GGPS1 (0.50) | GGPS1FDPSGPR84NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL9121777 | 0.84 | GGPS1 (0.54) | GGPS1FDPSGPR84NPC1RAB9A | |
| SCHEMBL17519485 | 0.84 | GGPS1 (0.54) | GGPS1FDPSGPR84NPC1RAB9A | |
| SCHEMBL3686302 | 0.84 | GGPS1 (0.54) | GGPS1FDPSGPR84NPC1RAB9A | |
| SCHEMBL1761303 | 0.83 | GGPS1 (0.53) | GGPS1FDPSGPR84NPC1RAB9A | |
| SCHEMBL28284831 | 0.83 | GGPS1 (0.52) | GGPS1FDPSGPR84NPC1RAB9A | |
| Beta-Alanine SCHEMBL4783165 | 0.81 | GGPS1 (0.48) | GGPS1FDPSGPR84NPC1RAB9A | |
| SCHEMBL20434857 | 0.80 | GGPS1 (0.50) | GGPS1FDPSGPR84NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112390794-B | Preparation method of minodronic acid key intermediate | 鲁南制药集团股份有限公司 | 2023-05-26 | — | — | CN | claimed |
| US-20090239898-A1 | FURTHER THERAPEUTIC USE OF ZOLPIDEM | SCIENCOM LTD. (GB) | 2009-09-24 | — | — | US | claimed |
| US-20080293947-A1 | Method of Preparation for Imidazolepyridines | MALLINCKRODT INC. | 2008-11-27 | — | — | US | claimed |
| EP-1966201-A1 | IMPROVED METHOD OF PREPARATION FOR IMIDAZOLEPYRIDINES | Mallinckrodt, Inc. (US) | 2008-09-10 | — | — | EP | claimed |
| WO-2007064444-A1 | IMPROVED METHOD OF PREPARATION FOR IMIDAZOLEPYRIDINES | MALLINCKRODT INC. (US) | 2007-06-07 | — | — | WO | claimed |
| US-20070043071-A1 | Further therapeutic use of zolpidem | SCIENCOM LTD. (GB) | 2007-02-22 | — | — | US | claimed |
| US-20070037843-A1 | Zolpidem hemitartrate | ARONHIME JUDITH | 2007-02-15 | — | — | US | claimed |
| EP-1624867-A1 | FURTHER THERAPEUTIC USE OF ZOLPIDEM | SCIENCOM LTD (GB) | 2006-02-15 | — | — | EP | claimed |
| WO-2004100948-A1 | FURTHER THERAPEUTIC USE OF ZOLPIDEM | SCIENCOM LTD (GB) | 2004-11-25 | — | — | WO | claimed |
| EP-0819002-B1 | USE OF IMIDAZO-[1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | CLARENDON TRADING & INVESTIMEN (PT) | 2002-08-28 | — | — | EP | claimed |
| EP-0819002-A1 | USE OF IMIDAZOL 1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | Clarendon-Trading & Investimentos LDA (PT) | 1998-01-21 | — | — | EP | claimed |
| WO-1996031210-A1 | USE OF IMIDAZO[1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | CLARENDON-TRADING & INVESTIMENTOS LDA (PT) | 1996-10-10 | — | — | WO | claimed |
| CN-118206547-A | Zolpidem-D7 compound and preparation method thereof | 公安部鉴定中心 | 2024-06-18 | — | — | CN | disclosed |
| CN-112390794-B | Preparation method of minodronic acid key intermediate | 鲁南制药集团股份有限公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-112390794-B | Preparation method of minodronic acid key intermediate | 鲁南制药集团股份有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20210300948-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | Frequency Therapeutics, Inc. | 2021-09-30 | — | — | US | disclosed |
| EP-0819002-A1 | USE OF IMIDAZOL 1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | Clarendon-Trading & Investimentos LDA (PT) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031210-A1 | USE OF IMIDAZO[1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | CLARENDON-TRADING & INVESTIMENTOS LDA (PT) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996031210-A1 | USE OF IMIDAZO[1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | CLARENDON-TRADING & INVESTIMENTOS LDA (PT) | 1996-10-10 | — | — | WO | disclosed |
| EP-0092459-A2 | Imidazo(1,2-a)pyridines, their preparation and therapeutical use | SYNTHELABO (FR) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300948-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | MCL1, PROX1, MKI67 | GGPS1 2205/4885FDPS 2644/4885GPR84 3489/4885 |
| US-20080293947-A1 | Method of Preparation for Imidazolepyridines | ITPA, QDPR, NISCH | GGPS1 685/4885FDPS 398/4885GPR84 4238/4885 |
| US-20070037843-A1 | Zolpidem hemitartrate | PTH1R, CYP26A1, GABRQ | GGPS1 706/4885FDPS 1157/4885GPR84 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.